The Thrombi-Stat device offers a problem-solving method for determining the International Normalised Ratio (INR) outcomes from a capillary whole blood sample.
Medical practitioners use the International Normalised Ratio (INR) test to measure how long it takes for blood to clot.This is referred to as a Prothrombin Test, also known as Protime (PT).
The patient’s INR levels are then subsequently calculated by the results of the PT test. The basis of this test is to determine whether the patient is within the ideal INR ‘target range’. For most patients prescribed the anticoagulant medication Warfarin, INR levels range between 2.0 and 3.0; however, each patient’s levels can differ depending on the circumstances.
If the test results are above or below the ideal target range, then patients are at risk of uncontrollable, dangerous bleeding or blood clots, respectively.
Four reasons why the Thrombi-Stat device should be
your first-choice solution for in-clinic INR testing
Thrombi-Stat delivers
compared to our competitors
The cost of our Thrombi-Stat wet test method is
compared to £3+ for dry strip testing
Our device provides near-patient INR testing with dosing calculations at the touch of a button
It is supported by a NEQAS quality assurance scheme, committing us to
Our test results have a super quick turnaround of
for single sample tests with analysis
Thrombi-Stat analyses samples of capillary whole blood, citrated whole blood and plasma, enabling the system to be used for INR capillary measurements with outpatients
Our in-clinic testing by experts is comparable to laboratory testing
Thrombi-Stat delivers
compared to our competitors
The cost of our Thrombi-Stat wet test method is
compared to £3+ for dry strip testing
Our test results have a super quick turnaround of
for single sample tests with analysis
Our device provides near-patient INR testing with dosing calculations at the touch of a button
It is supported by a NEQAS quality assurance scheme, committing us to
Thrombi-Stat analyses samples of capillary whole blood, citrated whole blood and plasma, enabling the system to be used for INR capillary measurements with outpatients
Our in-clinic testing by experts is comparable to laboratory testing
The Fiix™ Test Kit is employed to ascertain a patient's anticoagulant status by combining it with a whole blood or plasma sample, thereby assessing the clotting ability.
Our Thromboplastin reagent is utilised for in vitro management of patient anticoagulant treatment through venous blood FIIX™ Prothrombin durations.
Fiix™ is generally more stable across a long period of time than regular PT, due to the included Fiix™ plasma acting as a natural control for the test. Using Fiix™ can improve clinical outcomes and reduce anticoagulation variability.
We work exclusively with the medical professionals that initiated the Fiix™ test. As their only partners in the development and production, we ensure the quality manufacture and distribution of the enhanced INR test.
The Hart Biologicals Fiix™ Test Kit, which includes the PT Assay reagent, has been featured on The Frisma Factor online in an article titled, 'The Fiix-PT Assay; Improves on PT-INR.'
‘I [Geo] received a communication from Dr. Pall Onundarson, Hematology Laboratory and Thrombosis and Hemostasis Service, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, about the Fiix-PT assay designed to monitor vitamin K antagonist [warfarin, Coumadin] therapy unaffected by reductions in FVII and FIX which the authors claim to play little role in clinical anticoagulation. I've attached two articles that describe the assay in detail. Dr. Onundarson speculates the assay could also be adapted to anti-Xa DOAC measurement.’
In response, Pall replied: ‘Thank you, George, for posting this. The FiixNR is a CE marked product available from www.hartbio.co.uk in Europe. In our two clinical studies monitoring warfarin with Fiix normalized ratio (FiixNR) instead of PT-INR, TE was reduced about 50% during long-term management. This appears to be due to stabilization of the anticoagulant effect by ignoring FVII. There was no increase in bleeding.
There is no question that unmonitored DOAC treatment is more convenient than warfarin. However, now the question remains to be answered how FiixNR monitored warfarin compares to the DOACs in terms of effectiveness and safety.
We hope to have better results by 2022. For patients who have to stay on warfarin for different reasons, we think a more stable effect would be better.
Hart Biologicals has been producing INR testing for many years, and FiixTM is the next generation of laboratory Prothrombin Time (PT) tests that have improved results and, in some cases, superior patient outcomes.
Our Thromboplastin reagent is utilised for in vitro management of patient anticoagulant treatment through venous blood FIIX™ Prothrombin durations.
Find out how to perform an INR Calibration using the Poller Calibrants® PT/INR Line Plasma Set Cat HB-4452-FG
